Differences in radiosensitivity between three HER2 overexpressing cell lines.
Steffen AC, Göstring L, Tolmachev V, Palm S, Stenerlöw B, Carlsson J.
Unit of Biomedical Radiation Sciences, Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, 751 85, Sweden.
http://www.ncbi.nlm.nih.gov/pubmed/1...ubmed_RVDocSum
"CONCLUSION: There can be differences in radiosensitivity, which, if they also exist between patient breast cancer cells, are important to consider for both conventional radiotherapy and for HER2-targeted radionuclide therapy."